文献速递肾小球疾病

LIF/JAK2/STAT1信号通路增强IgA肾病扁桃体来源细胞系产生半乳糖缺陷型IgA1

LIF/JAK2/STAT1 Signaling Enhances Production of Galactose-Deficient IgA1 by IgA1-Producing Cell Lines Derived From Tonsils of Patients With IgA Nephropathy.
PubMed 文献 · Kidney Int Rep · 2023-11-11

该研究利用IgA肾病(IgAN)或阻塞性睡眠呼吸暂停(OSA)患者扁桃体来源的永生化IgA1产生细胞系,发现IgAN来源细胞产生更多半乳糖缺陷型IgA1(Gd-IgA1),且对白血病抑制因子(LIF)而非制瘤素M(OSM)有升高Gd-IgA1产生的反应。该效应与STAT1磷酸化失调相关,JAK2抑制剂AZD1480可剂量依赖性抑制LIF诱导的Gd-IgA1过度产生,高浓度AZD1480仅在LIF存在时将IgAN来源细胞的Gd-IgA1产生降至OSA对照细胞水平。

要点

  • IgAN扁桃体来源细胞系产生Gd-IgA1多于OSA来源细胞,且对LIF刺激有过度反应。
  • LIF诱导的Gd-IgA1过度产生与STAT1磷酸化失调相关,JAK2抑制剂可抑制该效应。
  • 高浓度AZD1480仅在LIF存在时可将IgAN细胞的Gd-IgA1产生降至对照水平。

核心结论

  • IgAN细胞因异常信号通路而表现出LIF介导的Gd-IgA1过度产生。
  • JAK2抑制剂可对抗LIF诱导的效应并阻断IgAN中Gd-IgA1的合成。

研究设计与样本

  • 使用源自IgAN或OSA患者扁桃体的永生化IgA1产生细胞系进行体外研究。
  • 通过凝集素酶联免疫吸附试验测定Gd-IgA1产生,免疫印迹评估JAK-STAT信号,并用siRNA敲低和小分子抑制剂验证。

主要发现

  • IgAN来源细胞产生的Gd-IgA1多于OSA来源细胞。
  • IgAN来源细胞对LIF而非OSM表现出Gd-IgA1产生升高。
  • 该效应与STAT1磷酸化失调相关,经STAT1 siRNA敲低确认。
  • JAK2抑制剂AZD1480剂量依赖性抑制LIF诱导的Gd-IgA1过度产生。
  • 高浓度AZD1480仅在LIF存在时,将IgAN来源细胞的Gd-IgA1产生降至OSA对照细胞水平。

临床怎么用

  • 提示JAK2抑制剂可能作为降低IgAN患者Gd-IgA1产生的潜在治疗策略。
  • 扁桃体来源细胞中LIF/JAK2/STAT1通路可能成为干预靶点。

局限性

  • 研究基于永生化细胞系体外实验,结论需在体内及临床研究中进一步验证。
  • 机制模型为基于LIF-LIFR-gp130-JAK2受体复合物建模的推测,尚未直接证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Galactose-deficient IgA1 (Gd-IgA1) plays a key role in the pathogenesis of IgA nephropathy (IgAN). Tonsillectomy has been beneficial to some patients with IgAN, possibly due to the removal of tonsillar cytokine-activated cells producing Gd-IgA1. To test this hypothesis, we used immortalized IgA1-producing cell lines derived from tonsils of patients with IgAN or obstructive sleep apnea (OSA) and assessed the effect of leukemia inhibitory factor (LIF) or oncostatin M (OSM) on Gd-IgA1 production. METHODS: Gd-IgA1 production was measured by lectin enzyme-linked immunosorbent assay; JAK-STAT signaling in cultured cells was assessed by immunoblotting of cell lysates; and validated by using small interfering RNA (siRNA) knock-down and small-molecule inhibitors. RESULTS: IgAN-derived cells produced more Gd-IgA1 than the cells from patients with OSA, and exhibited elevated Gd-IgA1 production in response to LIF, but not OSM. This effect was associated with dysregulated STAT1 phosphorylation, as confirmed by STAT1 siRNA knock-down. JAK2 inhibitor, AZD1480 exhibited a dose-dependent inhibition of the LIF-induced Gd-IgA1 overproduction. Unexpectedly, high concentrations of AZD1480, but only in the presence of LIF, reduced Gd-IgA1 production in the cells derived from patients with IgAN to that of the control cells from patients with OSA. Based on modeling LIF-LIFR-gp130-JAK2 receptor complex, we postulate that LIF binding to LIFR may sequester gp130 and/or JAK2 from other pathways; and when combined with JAK2 inhibition, enables full blockade of the aberrant O-glycosylation pathways in IgAN. CONCLUSION: In summary, IgAN cells exhibit LIF-mediated overproduction of Gd-IgA1 due to abnormal signaling. JAK2 inhibitors can counter these LIF-induced effects and block Gd-IgA1 synthesis in IgAN.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Yamada K, Huang ZQ, Reily C, et al. LIF/JAK2/STAT1 Signaling Enhances Production of Galactose-Deficient IgA1 by IgA1-Producing Cell Lines Derived From Tonsils of Patients With IgA Nephropathy. Kidney Int Rep. 2023. PMID: 38344714. doi:10.1016/j.ekir.2023.11.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。